Default company panoramic image

BioAegis Therapeutics, Inc.

BioAegis Therapeutics Inc. is a newly formed, clinical stage entity developing novel protein replacement therapies based on plasma gelsolin.

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York City, NY, USA
  • Currency USD
  • Employees 5
  • Website

Company Summary

BioAegis is a newly formed, Phase 2 company commercializing biomarker-driven therapies based on recent groundbreaking discoveries of Dr. Thomas Stossel, Harvard Med./Brigham and Womens. Products involve plasma gelsolin, a human protein for replacement therapy with a unique profile of protecting against inflammation while supporting immunity. Ph1b/2a data in critical care. This funding achieves US IND-ready with manufacturing and diagnostic.


  • Default avatar
    Susan L. Levinson, Ph.D.
    Chief Executive Officer, Founder

    Susan Levinson is a healthcare executive with life sciences consulting and pharma experience with leadership roles from the lab bench to marketing. At Novartis, she managed medical education, partnering and launch for a CV product, New Product Marketing, and Licensing, as well as Marketing Planning. She also led an R&D re-engineering team and project team for US registration. Her career began in Research, managing drug discovery programs.

  • Default avatar
    Valerie Ceva
    Chief Operating Officer, Founder

    Valerie Ceva, is a health care executive with a successful track record in life science business development, strategic consulting and global venture capital transactions. This includes years of experience in operational and leadership roles with major pharmaceutical firms (Novartis, Ciba-Geigy) and healthcare start-ups (I-Trax) as well as in consulting and private equity/venture capital (Flagship, Accel).

  • Default avatar
    Steven Cordovano
    VP Corporate Development, Founder

    As Vice President of Corporate Communications and Investor Relations, Steven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience, having actually been a highly successful fund manager. He has worked in finance and life science portfolio management for 25 years.

  • Default avatar
    Thomas Stossel, M.D.
    Chairman, Scientific Advisory Board, Founder

    Dr. Thomas P. Stossel is a Senior Physician and Head of Translational Medicine at Boston’s Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and founder and scientific advisor of BioAegis. He is the discover of gelsolin and the world's expert on this protein.

  • Default avatar
    Po-Shun Lee, M.D.
    Clinical Advisory Board Member, Founder

    Dr. Po-Shun Lee is a critical care specialist and gelsolin researcher with extensive experience on the protein. He is also a Harvard Medical School Instructor. Dr. Lee spent years in Dr. Stossel's group and was responsible for the key biomarker and assay development as well as was the liaison to investigators for the Phase 1/2a trials.


  • Default avatar
    Christopher Denn, Goodwin Procter, LLP (Boston)
    Default avatar
    Clinical Advisors: Derek Angus, MD, MPH, U of Pittsburgh School of Med; Steven Opal, MD, Brown University School of Med; B. Taylor Thompson, MD, Harvard Med School, Mass Gen; Atul Malhotra, MD, Harvard Med School

Previous Investors

  • Default avatar
    Founding Team has financed IP licensing and patent administration cost. $70,000+
    Default avatar
    Leveraging investments made by Biogen prior to discovery of IP licensed by BioAegis(Full tox/manuf)